Transcatheter Technologies GmbH said it raised the 2nd tranche in its Series B round for its 3rd-generation replacement heart valve.
The tranche takes the German transcatheter aortic heart implant developer’s total raise to nearly $7.2 million, a spokesman told MassDevice.com this morning.
In March, Transcatheter Tech. revealed 6-month data on its Trinity TAVI device, saying the results showed no incidence of the paravalvular leakage that’s plagued earlier generations of TAVI devices. The special sauce in the Trinity device the ability to fully reposition it even after complete deployment. A physician can implant the device, test its function and placement, then retract the system and shift its position if necessary.
Founder & CEO Dr. Wolfgang Goetz is looking to woo additional investors at the Cardiovascular Research Foundation’s TVT 2014 meeting in Vancouver later this week, according to a press release.
“A severe limitation of currently marketed TAVI systems is that they cannot be repositioned once fully implanted. On the other hand, Trinity is designed to solve this life-threatening issue and thereby potentially reduces the unwanted consequences of PVL and AV block," Goetz, a cardiac surgeon, said in prepared remarks. "Once our Trinity valve is completely expanded and anchored above the annulus, a cardiologist can then fully assess the valve’s function to determine whether it needs to be repositioned, retrieved, or kept in the same position. This feature is absolutely unique to Trinity, which is why we have positioned Trinity as a 3rd-generation TAVI system."